Showing 1741-1750 of 2314 results for "".
- Market Scope: Safer and More Effective Glaucoma Surgical Options Expected to Double Global Revenue by 2027https://modernod.com/news/market-scope-safer-and-more-effective-glaucoma-surgical-options-expected-to-double-global-revenue-by-2027/2481223/Nearly 48 million individuals are diagnosed with glaucoma globally, but just over a million, or 2.2 percent, will have surgery in 2022. However, safer and more effective surgical devices over the next 5 years will increase the percentage of glaucoma patients treated surgically to a projected 3.5
- Mitochondria Double as Tiny Lenses in the Eyehttps://modernod.com/news/mitochondria-double-as-tiny-lenses-in-the-eye/2480799/A new report by Wired details a study that found that inside mammalian eyes, mitochondria, the organelles that power cells, may serve a second role as microscopic lenses, helping t
- ProQR Does Not Meet Primary or Secondary Endpoints in Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-Mediated LCA10https://modernod.com/news/proqr-does-not-meet-primary-or-secondary-endpoints-phase-23-illuminate-trial-of-sepofarsen-in-cep290-mediated-lca10/2480633/
- ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosahttps://modernod.com/news/proqr-announces-first-patients-dosed-in-phase-23-pivotal-trials-of-qr-421a-for-ush2a-mediated-retinitis-pigmentosa/2480522/
- First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Oxurion's THR-149 vs Aflibercept for Treatment of DMEhttps://modernod.com/news/first-patient-dosed-in-part-b-of-phase-2-kalahari-study-evaluating-oxurions-thr-149-vs-aflibercept-for-treatment-of-dme/2480445/
- iCare USA to Commercialize Oculo Software Solution Platform that Connects Doctors with Each Other and Their Patientshttps://modernod.com/news/icare-usa-to-commercialize-oculo-software-solution-platform-that-connects-doctors-with-each-other-and-their-patients/2480379/iCare USA’s parent company, Revenio, has announced its acquisition of Ocu
- Prevent Blindness: Senate FY2022 Appropriations Bill Doubles Funding for the CDC’s Vision and Eye Health Programhttps://modernod.com/news/prevent-blindness-senate-fy2022-appropriations-bill-doubles-funding-for-the-cdcs-vision-and-eye-health-program/2480364/This week, the Senate Appropriations Committee released its proposed legislation to fund programs under the Department of Health and Human Services in Fiscal Year (FY) 2022. "As a result of continued Prevent Blindness advocacy efforts, the Senate Appropriations legislation includes
- Oxurion Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-announces-first-patient-dosed-in-its-phase-2-study-evaluating-thr-687-for-the-treatment-of-dme/2480349/Oxurion announced that the first patient h
- Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growthhttps://modernod.com/news/glaucoma-devices-expanding-role-to-drive-double-digit-market-growth/2479465/Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical devi
- First Pediatric Patient with Rare Genetic Eye Disease Dosed in Clinical Trialhttps://modernod.com/news/first-pediatric-patient-with-rare-genetic-eye-disease-dosed-in-clinical-trial/2479207/ProQR Therapeutics has announced the first pediatric clinical trial participant has been treated in its new clinical trial named Brighten of the experimental RNA therapy sepofarsen. Brighten is a clinical study for children under 8 years old with Leber congenital amaurosis (LCA) d